Jacobs Levy Equity Management
ALDX icon

Jacobs Levy Equity Management’s Aldeyra Therapeutics ALDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Sell
796,816
-171,935
-18% -$753K 0.01% 660
2025
Q4 		$5.02M Buy
968,751
+21,200
+2% +$109K 0.02% 410
2025
Q3 		$4.95M Buy
947,551
+313,395
+49% +$1.63M 0.02% 428
2025
Q2 		$2.43M Buy
634,156
+596,172
+1,570% +$1.54M 0.01% 583
2025
Q1 		$218K Buy
+37,984
New +$225K ﹤0.01% 1020
2024
Q4 		– Sell
-476,949
Closed -$2.57M – 930
2024
Q3 		$2.57M Buy
476,949
+295,864
+163% +$1.41M 0.01% 558
2024
Q2 		$599K Buy
181,085
+2,166
+1% +$8.48K ﹤0.01% 816
2024
Q1 		$585K Buy
+178,919
New +$589K ﹤0.01% 803
2023
Q1 		– Sell
-21,374
Closed -$149K – 950
2022
Q4 		$149K Sell
21,374
-260,462
-92% -$1.49M ﹤0.01% 916
2022
Q3 		$1.5M Buy
281,836
+47,166
+20% +$283K 0.01% 615
2022
Q2 		$936K Buy
+234,670
New +$807K 0.01% 767
2021
Q3 		– Sell
-43,069
Closed -$488K – 1027
2021
Q2 		$488K Hold
43,069
– – ﹤0.01% 864
2021
Q1 		$512K Sell
43,069
-254,763
-86% -$2.93M ﹤0.01% 860
2020
Q4 		$2.04M Sell
297,832
-8,002
-3% -$56.2K 0.02% 582
2020
Q3 		$2.27M Buy
305,834
+795
+0.3% +$5.13K 0.02% 498
2020
Q2 		$1.27M Buy
305,039
+260,076
+578% +$950K 0.01% 620
2020
Q1 		$111K Buy
44,963
+17,131
+62% +$77K ﹤0.01% 953
2019
Q4 		$162K Buy
+27,832
New +$161K ﹤0.01% 954

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's ALDX Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Aldeyra Therapeutics (ALDX) stake by 18% in Q1 2026, selling an estimated $753K and leaving 796,816 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #660.

Jacobs Levy Equity Management first reported a position in ALDX in Q4 2019 and has held it in 18 quarters since. The position peaked at $5.02M in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Jacobs Levy Equity Management held 796,816 shares of Aldeyra Therapeutics worth $1.35M as of Q1 2026.
  • Jacobs Levy Equity Management sold 171,935 Aldeyra Therapeutics shares in Q1 2026, an estimated $753K.
  • Aldeyra Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #660 holding.
  • Jacobs Levy Equity Management first reported a position in Aldeyra Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • Jacobs Levy Equity Management's Aldeyra Therapeutics position peaked at $5.02M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.